Upcoming Event

The Evolving Landscape of Cutaneous Squamous Cell Carcinoma Treatment: Updates on Immunotherapy Treatment

Wednesday, October 30, 2019 6:30 p.m. EST

Approximate running time: 1 hour


Marcus Butler, MD

Cutaneous Squamous Cell Carcinoma (cSCC) is the second most common form of skin cancer in Canada, with an estimated 16,000+ patients nationally. It is forecasted that anywhere from 200-700 of these patients have locally advanced or metastatic cSCC.

This livestreaming program targets surgeons from a number of specialties that are involved in the treatment of cSCC patients, to advise on a new, recently approved curative treatment. Cemiplimab is a fully-human monoclonal antibody that is the first and only biologic immunotherapy treatment specifically approved and available for adult patients with metastatic or locally advanced cSCC.

Program Description

Language: English

Therapeutic area: Skin Cancer